{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:43:29Z","timestamp":1791089009393,"version":"4.1.0"},"reference-count":0,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2011.00028","type":"journal-article","created":{"date-parts":[[2011,6,14]],"date-time":"2011-06-14T01:14:00Z","timestamp":1308014040000},"source":"Crossref","is-referenced-by-count":42,"title":["Alpha 2 Delta (\u03b12\u03b4) Ligands, Gabapentin and Pregabalin: What is the Evidence for Potential Use of These Ligands in Irritable Bowel Syndrome"],"prefix":"10.3389","volume":"2","author":[{"given":"Jeremy D.","family":"Gale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley A.","family":"Houghton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2011]]},"container-title":["Frontiers in Pharmacology"],"original-title":[],"deposited":{"date-parts":[[2015,2,18]],"date-time":"2015-02-18T14:46:47Z","timestamp":1424270807000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2011.00028\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":0,"URL":"https:\/\/doi.org\/10.3389\/fphar.2011.00028","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}